CORC

在结果中检索

CORC

浏览/检索结果: 共53条，第1-10条 帮助

限定条件                    
已选(0)清除 条数/页：   排序方式：
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
Link prediction with signed latent factors in signed social networks 会议论文
作者:  Xu, Pinghua;  Wu, Jia;  Hu, Wenbin;  Du, Bo
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
Review: Genetic algorithm application in gesture recognition 会议论文
作者:  Yu, Mingchao;  Li, Gongfa;  Sun, Ying;  Tao, Bo;  Xu, Shuang
收藏  |  浏览/下载：1/0  |  提交时间：2019/12/05
Image segmentation technology based on genetic algorithm 会议论文
作者:  Tan, Chong;  Sun, Ying;  Li, Gongfa;  Tao, Bo;  Xu, Shuang
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
An event-oriented backpressure scheduling scheme for internet of vehicles 会议论文
作者:  Mei, Lishi;  Xu, Ning;  Yin, Bo
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：38/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
Research on key technologies of software-defined network based on blockchain 会议论文
作者:  Xue, Chenyu;  Xu, Ning;  Bo, Yin
收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05
Semisupervised cross-media retrieval by distance-preserving correlation learning and multi-modal manifold regularization 会议论文
作者:  Wang, Ting;  Zhang, Hong;  Li, Bo;  Xu, Xin
收藏  |  浏览/下载：1/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：30/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace